Talis Biomedical (TLIS) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access TLIS Annual Balance Sheets →
A period-by-period view of the balance sheet from Talis Biomedical to Jun 30 2023 helps clarify how Jun 30 2024's financial structure has changed over time.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2024)
(Mar 31 2024) (Dec 31 2023) (Sep 30 2023) (Jun 30 2023)
Assets
Cash & cash equivalent59.87
Cash & Short-term Investments59.00
Accounts receivable0.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current3.73
Total Current Assets63.60
Equipment/Property/Plant Net0.43
Other Assets, Noncurrent2.00
Restricted Cash Current-
Operating Lease Right Of Use Asset7.91
Total Assets72.70
Liabilities
Accounts Payable, Current AC3.79
Accrued Liabilities, Current AC0.63
Other Liabilities, Current3.77
Total Current Liabilities8.20
Total Long-term Debt0.00
Other liabilities, Noncurrent15.88
OperatingLeaseLiabilityNoncurrent15.88
Accrued Compensation Current0.85
Operating Lease Liability Current2.92
Total Liabilities24.07
Stockholders' Equity
Additional Paid In Capital Common Stock610.47
Retained Earnings / Accumulated Deficit-561.85
Other Equity0.00
Common Stockholder's Equity48.62
Preferred Stockholder's Equity0.00
Total Stockholder's Equity48.63
Liabilities & Stockholder's Equity72.70
4 historic quarters locked

Sign in to unlock the full Talis Biomedical balance sheet history.

About Talis Biomedical Corp Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000950170-24-098525

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.